OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Innate and Adaptive Immune Response in Fabry Disease
Wladimir Mauhin, Olivier Lidove, Elisa Masat, et al.
JIMD Reports (2015), pp. 1-10
Open Access | Times Cited: 79
Wladimir Mauhin, Olivier Lidove, Elisa Masat, et al.
JIMD Reports (2015), pp. 1-10
Open Access | Times Cited: 79
Showing 1-25 of 79 citing articles:
Cardiac Involvement in Fabry Disease
Maurizio Pieroni, James Moon, Eloisa Arbustini, et al.
Journal of the American College of Cardiology (2021) Vol. 77, Iss. 7, pp. 922-936
Open Access | Times Cited: 209
Maurizio Pieroni, James Moon, Eloisa Arbustini, et al.
Journal of the American College of Cardiology (2021) Vol. 77, Iss. 7, pp. 922-936
Open Access | Times Cited: 209
Contribution of inflammatory pathways to Fabry disease pathogenesis
Paula Rozenfeld, Sandro Feriozzi
Molecular Genetics and Metabolism (2017) Vol. 122, Iss. 3, pp. 19-27
Open Access | Times Cited: 187
Paula Rozenfeld, Sandro Feriozzi
Molecular Genetics and Metabolism (2017) Vol. 122, Iss. 3, pp. 19-27
Open Access | Times Cited: 187
Neuroinflammatory paradigms in lysosomal storage diseases
Megan E. Bosch, Tammy Kielian
Frontiers in Neuroscience (2015) Vol. 9
Open Access | Times Cited: 119
Megan E. Bosch, Tammy Kielian
Frontiers in Neuroscience (2015) Vol. 9
Open Access | Times Cited: 119
Glycosphingolipids and neuroinflammation in Parkinson’s disease
Karim Bélarbi, Elodie Cuvelier, Marie-Amandine Bonte, et al.
Molecular Neurodegeneration (2020) Vol. 15, Iss. 1
Open Access | Times Cited: 111
Karim Bélarbi, Elodie Cuvelier, Marie-Amandine Bonte, et al.
Molecular Neurodegeneration (2020) Vol. 15, Iss. 1
Open Access | Times Cited: 111
Mild Innate Immune Activation Overrides Efficient Nanoparticle‐Mediated RNA Delivery
Melissa P. Lokugamage, Zubao Gan, Chiara Zurla, et al.
Advanced Materials (2019) Vol. 32, Iss. 1
Open Access | Times Cited: 101
Melissa P. Lokugamage, Zubao Gan, Chiara Zurla, et al.
Advanced Materials (2019) Vol. 32, Iss. 1
Open Access | Times Cited: 101
Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy
Frank DeRosa, L Smith, Yinghua Shen, et al.
Molecular Therapy (2019) Vol. 27, Iss. 4, pp. 878-889
Open Access | Times Cited: 91
Frank DeRosa, L Smith, Yinghua Shen, et al.
Molecular Therapy (2019) Vol. 27, Iss. 4, pp. 878-889
Open Access | Times Cited: 91
Current and Investigational Therapeutics for Fabry Disease
Andrew Felis, Michael Whitlow, Abigayle Kraus, et al.
Kidney International Reports (2019) Vol. 5, Iss. 4, pp. 407-413
Open Access | Times Cited: 80
Andrew Felis, Michael Whitlow, Abigayle Kraus, et al.
Kidney International Reports (2019) Vol. 5, Iss. 4, pp. 407-413
Open Access | Times Cited: 80
Inflammation across the spectrum of hypertrophic cardiac phenotypes
Rosa Lillo, Francesca Graziani, Francesco Franceschi, et al.
Heart Failure Reviews (2023) Vol. 28, Iss. 5, pp. 1065-1075
Open Access | Times Cited: 29
Rosa Lillo, Francesca Graziani, Francesco Franceschi, et al.
Heart Failure Reviews (2023) Vol. 28, Iss. 5, pp. 1065-1075
Open Access | Times Cited: 29
An expert consensus on the recommendations for the use of biomarkers in Fabry disease
Alessandro P. Burlina, Eva Brand, Derralynn Hughes, et al.
Molecular Genetics and Metabolism (2023) Vol. 139, Iss. 2, pp. 107585-107585
Open Access | Times Cited: 22
Alessandro P. Burlina, Eva Brand, Derralynn Hughes, et al.
Molecular Genetics and Metabolism (2023) Vol. 139, Iss. 2, pp. 107585-107585
Open Access | Times Cited: 22
Anderson–Fabry disease management: role of the cardiologist
Maurizio Pieroni, Mehdi Namdar, Iacopo Olivotto, et al.
European Heart Journal (2024) Vol. 45, Iss. 16, pp. 1395-1409
Open Access | Times Cited: 13
Maurizio Pieroni, Mehdi Namdar, Iacopo Olivotto, et al.
European Heart Journal (2024) Vol. 45, Iss. 16, pp. 1395-1409
Open Access | Times Cited: 13
Inflammation in Fabry disease: stages, molecular pathways, and therapeutic implications
Hibba Kurdi, Lucia Lavalle, James Moon, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 10
Hibba Kurdi, Lucia Lavalle, James Moon, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 10
Overview of immune abnormalities in lysosomal storage disorders
Donato Rigante, Clelia Cipolla, Umberto Basile, et al.
Immunology Letters (2017) Vol. 188, pp. 79-85
Closed Access | Times Cited: 85
Donato Rigante, Clelia Cipolla, Umberto Basile, et al.
Immunology Letters (2017) Vol. 188, pp. 79-85
Closed Access | Times Cited: 85
Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease
Malte Lenders, Eva Brand
Journal of the American Society of Nephrology (2018) Vol. 29, Iss. 9, pp. 2265-2278
Open Access | Times Cited: 81
Malte Lenders, Eva Brand
Journal of the American Society of Nephrology (2018) Vol. 29, Iss. 9, pp. 2265-2278
Open Access | Times Cited: 81
Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction
Haran Yogasundaram, Anish Nikhanj, Brendan Putko, et al.
Journal of the American Heart Association (2018) Vol. 7, Iss. 21
Open Access | Times Cited: 76
Haran Yogasundaram, Anish Nikhanj, Brendan Putko, et al.
Journal of the American Heart Association (2018) Vol. 7, Iss. 21
Open Access | Times Cited: 76
Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease
Malte Lenders, Leon Paul Neußer, Michael Rudnicki, et al.
Journal of the American Society of Nephrology (2018) Vol. 29, Iss. 12, pp. 2879-2889
Open Access | Times Cited: 63
Malte Lenders, Leon Paul Neußer, Michael Rudnicki, et al.
Journal of the American Society of Nephrology (2018) Vol. 29, Iss. 12, pp. 2879-2889
Open Access | Times Cited: 63
Immune‐Mediated Myocarditis in Fabry Disease Cardiomyopathy
Andrea Frustaci, Romina Verardo, Claudia Del Grande, et al.
Journal of the American Heart Association (2018) Vol. 7, Iss. 17
Open Access | Times Cited: 61
Andrea Frustaci, Romina Verardo, Claudia Del Grande, et al.
Journal of the American Heart Association (2018) Vol. 7, Iss. 17
Open Access | Times Cited: 61
Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease
Sanne J. van der Veen, Wytze J. Vlietstra, Laura van Dussen, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 16, pp. 5784-5784
Open Access | Times Cited: 56
Sanne J. van der Veen, Wytze J. Vlietstra, Laura van Dussen, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 16, pp. 5784-5784
Open Access | Times Cited: 56
Therapeutic Approaches in Lysosomal Storage Diseases
Carlos Fernández-Pereira, Beatriz San Millán, María Gallardo‐Gómez, et al.
Biomolecules (2021) Vol. 11, Iss. 12, pp. 1775-1775
Open Access | Times Cited: 44
Carlos Fernández-Pereira, Beatriz San Millán, María Gallardo‐Gómez, et al.
Biomolecules (2021) Vol. 11, Iss. 12, pp. 1775-1775
Open Access | Times Cited: 44
Lysosomes in the immunometabolic reprogramming of immune cells in atherosclerosis
Fabrizia Bonacina, Xiangyu Zhang, Nicolas Manel, et al.
Nature Reviews Cardiology (2024)
Closed Access | Times Cited: 7
Fabrizia Bonacina, Xiangyu Zhang, Nicolas Manel, et al.
Nature Reviews Cardiology (2024)
Closed Access | Times Cited: 7
X Chromosome Inactivation in Carriers of Fabry Disease: Review and Meta-Analysis
Emanuela Viggiano, Luisa Politano
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7663-7663
Open Access | Times Cited: 39
Emanuela Viggiano, Luisa Politano
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7663-7663
Open Access | Times Cited: 39
Anderson-Fabry disease cardiomyopathy: an update on epidemiology, diagnostic approach, management and monitoring strategies
Tauben Averbuch, James A. White, Nowell M. Fine
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 14
Tauben Averbuch, James A. White, Nowell M. Fine
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 14
Fabry Disease: Cardiac Implications and Molecular Mechanisms
David Weissman, Jan Dudek, Vasco Sequeira, et al.
Current Heart Failure Reports (2024) Vol. 21, Iss. 2, pp. 81-100
Open Access | Times Cited: 5
David Weissman, Jan Dudek, Vasco Sequeira, et al.
Current Heart Failure Reports (2024) Vol. 21, Iss. 2, pp. 81-100
Open Access | Times Cited: 5
Anxiety-like behavior and altered hippocampal activity in a transgenic mouse model of Fabry disease
Kai K. Kummer, Jeiny Luna Choconta, Marie-Luise Edenhofer, et al.
Neurobiology of Disease (2025), pp. 106797-106797
Open Access
Kai K. Kummer, Jeiny Luna Choconta, Marie-Luise Edenhofer, et al.
Neurobiology of Disease (2025), pp. 106797-106797
Open Access
Sex Differences in Circulating Inflammatory, Immune, and Tissue Growth Markers Associated with Fabry Disease-Related Cardiomyopathy
Margarita M. Ivanova, Julia Dao, Andrew Friedman, et al.
Cells (2025) Vol. 14, Iss. 5, pp. 322-322
Open Access
Margarita M. Ivanova, Julia Dao, Andrew Friedman, et al.
Cells (2025) Vol. 14, Iss. 5, pp. 322-322
Open Access
Commentary on ‘Lentivirus‐mediated gene therapy for Fabry disease: 5‐year end‐of‐study results from the Canadian FACTS trial’
Alessandro Rossi, Nicola Brunetti‐Pierri
Clinical and Translational Discovery (2025) Vol. 5, Iss. 2
Open Access
Alessandro Rossi, Nicola Brunetti‐Pierri
Clinical and Translational Discovery (2025) Vol. 5, Iss. 2
Open Access
